Learn which CINV therapy is preferred by 2 major oncology guidelines

  
  If you prefer, you can view this message in your browser.


  
2 major oncology guidelines agree: palonosetron (ALOXI(R)) is the preferred 5-HT3 RA(1,2*) ALOXI(R) (palonosetron HCl injection) 0.25 mg/5 mL
Learn why ALOXI is the preferred 5-HT3 option
*Palonosetron received 'preferred' status designation for prevention of acute and delayed emesis following IV moderately emetogenic chemotherapy.
 
 
Indication
 
ALOXI injection is indicated in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic chemotherapy, and the prevention of acute nausea and vomiting associated with initial and repeat courses of highly emetogenic chemotherapy.
 
Important Safety Information
 
Contraindications
 
• ALOXI is contraindicated in patients known to have hypersensitivity to the drug or any of its components
 
Please see below for additional Important Safety Information.
 
Palonosetron (ALOXI): the preferred therapy for CINV following MEC1,2
 
The only FDA-approved IV 5-HT3 receptor antagonist (RA) indicated to prevent acute and delayed CINV following MEC1,3
 
National Comprehensive Cancer Network(R) (NCCN(R)) and American Society of Clinical Oncology (ASCO): preferred 5-HT3 RA use in MEC
 
 
  CINV=chemotherapy-induced nausea and vomiting.
MEC=moderately emetogenic chemotherapy.		  
 
 
 
Learn More
 
 
Important Safety Information (continued)
 
Warnings and Precautions
 
• Hypersensitivity reactions, including anaphylaxis, have been reported with or without known hypersensitivity to other 5-HT3 receptor antagonists
 
• Serotonin syndrome has been reported with 5-HT3 receptor antagonists alone, but particularly with the use of serotonergic drugs. Serotonin syndrome can be life threatening. Symptoms may include the following combination of signs and symptoms: mental status changes, autonomic instability, neuromuscular symptoms, seizures, and gastrointestinal symptoms. Patients should be monitored for the emergence of serotonin syndrome, and if symptoms occur, discontinue ALOXI and initiate supportive treatment. Patients should be informed of the increased risk of serotonin syndrome, especially if ALOXI is used concomitantly with other serotonergic drugs
 
Adverse Reactions
 
• In adults, the most commonly reported adverse drug reactions include headache (9%) and constipation (5%)
 
For more information about ALOXI, please see Full Prescribing Information.
 
References: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis V.2.2016. © National Comprehensive Cancer Network, Inc 2016. All rights reserved. Accessed March 24, 2016. To view the most recent and complete version of the guideline, go online to NCCN.o‌rg. NATIONAL COMPREHENSIVE CANCER NETWORK®, NCCN®, NCCN GUIDELINES®, and all other NCCN Content are trademarks owned by the National Comprehensive Cancer Network, Inc. 2. Hesketh PJ, Bohlke K, Lyman GH, et al. Antiemetics: American Society of Clinical Oncology focused guideline update. J Clin Oncol. 2016;34:381-386. 3. ALOXI® (palonosetron HCI) injection. Full Prescribing Information.
 
This is a post-only mailing. Please do not reply to this email.

If you prefer not to receive further messages from this sender, please click here and confirm your request.
 
 
 
 
Eisai logo Helsinn logo
 
ALOXI® is a registered trademark of Helsinn Healthcare SA, Switzerland, used under license.
Distributed by Eisai Inc. under license of Helsinn Healthcare SA, Switzerland.
Marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc.
Eisai, Inc. 100 Tice Boulev‌ard, Woodcliff Lake, N‌J 07‌677 - (USA).
 
Helsinn Therapeutics, 170 Wood Av‌enue South, 5th Floor, Iselin, NJ 06‌830 - (USA).
 
© 2016 Eisai Inc. All rights reserved. ALOX-US0095(1) 0‌8/‌16